LINC01977通过靶向miR-212-3p/GOLM1轴促进乳腺癌进展及对多柔比星的化疗耐药性。

LINC01977 Promotes Breast Cancer Progression and Chemoresistance to Doxorubicin by Targeting miR-212-3p/GOLM1 Axis.

作者信息

Li Zheng, Li Yaming, Wang Xiaolong, Liang Yiran, Luo Dan, Han Dianwen, Li Chen, Chen Tong, Zhang Hanwen, Liu Ying, Wang Zekun, Chen Bing, Wang Lijuan, Zhao Wenjing, Yang Qifeng

机构信息

Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, China.

Pathology Tissue Bank, Qilu Hospital of Shandong University, Jinan, China.

出版信息

Front Oncol. 2021 Mar 31;11:657094. doi: 10.3389/fonc.2021.657094. eCollection 2021.

DOI:10.3389/fonc.2021.657094

PMID:33869063

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8046671/

Abstract

Long non-coding RNAs(lncRNAs) play an important role in cancer initiation and progression. However, hub lncRNAs involved in breast cancer still remain underexplored. In this study, integrated bioinformatics analysis was used to define LINC01977 as a key oncogenic driver in breast cancer. Subsequently, assays showed that LINC01977 could significantly promote breast cancer progression and chemoresistance to doxorubicin. To further investigate its biological mechanism, we performed dual-luciferase reporter assay, real-time PCR, RNA immunoprecipitation (RIP), and rescue assay. Our results indicated that LINC01977 may function as ceRNA to prevent GOLM1 gene from miRNA-mediated repression by sponging miR-212-3p. Overall, LINC01977 can serve as a novel prognostic indicator, and help develop more effective therapeutic approaches for breast cancer patients.

摘要

长链非编码RNA（lncRNAs）在癌症的发生和发展中起着重要作用。然而，参与乳腺癌的关键lncRNAs仍未得到充分研究。在本研究中，通过综合生物信息学分析将LINC01977定义为乳腺癌中的关键致癌驱动因子。随后的实验表明，LINC01977可显著促进乳腺癌进展以及对阿霉素的化疗耐药性。为进一步探究其生物学机制，我们进行了双荧光素酶报告基因检测、实时定量PCR、RNA免疫沉淀（RIP）及挽救实验。我们的结果表明，LINC01977可能作为竞争性内源RNA（ceRNA），通过结合miR-212-3p来阻止GOLM1基因受到miRNA介导的抑制作用。总体而言，LINC01977可作为一种新的预后指标，并有助于为乳腺癌患者开发更有效的治疗方法。